News and Trends 18 Jan 2016
Where there be Patent-Free Markets: Swiss-Swedish Biosimilar for Blindess Reaches Iran
Helvetic BioPharma (Switzerland) estimates that 70,000 people suffer from age-related macular degeneration in Iran, the leading cause of blindness. This deal with Xbrane in Stockholm (Sweden) will debut a biosimilar therapy that could really tackle this problem. Xbrane itself is a Swedish biopharma with links to Italy (after an acquisition of the Italian Primm Pharma […]